Prospective, randomized, single site study to determine the safety and effectiveness of
performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with
corneal ectasia or progressive keratoconus.
Subjects are randomized to a control group or a treatment group, with the control group
crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is
performed as a single treatment. Subjects are followed for at least 12 months to evaluate
the long term effects of corneal collagen cross-linking.
Subjects may be referred from other physicians but must return to Emory Vision for
completion of all study visits.
- Diagnosis of keratoconus with documented progression over the previous 12 months.
- Diagnosis of corneal ectasia
- Must be able to complete all study visits
- Prior corneal surgery in the keratoconus group
- Corneal scarring